Pharma & Biotech: 2017 Review of Outsourced Manufacturing
Foreword
I am pleased to introduce you to our 2017 review of the outsourced manufacturing sector, where we share some of the trends observed in recent years and look to the future of the industry. In the last five years, the industry has enjoyed positive growth and there are certainly positive indications for the future. The team at Results Healthcare has been very busy serving a range of client needs, helping both buyers and sellers to achieve their strategic goals. We have grown and broadened the healthcare team in response to the firm’s clients’ demands.
2016 ended with uncertainties concerning the future of ‘Obamacare’ under the incoming US administration and debates on the outcome of the British referendum on membership of the European Union (EU) as well as the performance of the Chinese and broader Asian economies in 2017. Regulators including the Food and Drug Administration (FDA) have shown a tougher stance regarding pharmaceutical manufacturers, which has disproportionately affected Asian suppliers. In May 2016, the EU agreed new stricter rules on medical devices and in vitro diagnostic medical devices. Industry leaders need to maintain their awareness of these issues as the marketplace seems likely to continue to become ever more stringently regulated, providing opportunities as well as threats. The healthcare providers, entrepreneurs and their suppliers will need to navigate through relevant changes, however, we remain very positive for the short and long term.
Looking towards the future, there are strong indications of above GDP growth for the outsourced manufacturing sector, which we discuss in this report. This is driven by greater demand for manufactured product as well as an anticipated rise in outsourcing. This climate will continue to create opportunities for deals, M&A and consolidation in the sector. Click here to see the full report.
Warm regards,
Kevin Bottomley
Healthcare Partner
Total Page Views: 829
